Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

INTRODUCTION: Available therapies for acute cough, a condition frequently caused by a viral upper respiratory tract infection (URTI), have shown limited evidence of efficacy. Gefapixant, a P2X3-receptor antagonist, has demonstrated efficacy and safety in studies of the treatment of refractory or une...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Jaclyn A., Kitt, Michael M., Bell, Alan, Noulin, Nicolas, Tzontcheva, Anjela, Seng, Megan McGratty, Lu, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458823/
https://www.ncbi.nlm.nih.gov/pubmed/35969360
http://dx.doi.org/10.1007/s41030-022-00193-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458823/
https://www.ncbi.nlm.nih.gov/pubmed/35969360
http://dx.doi.org/10.1007/s41030-022-00193-w

Ejemplares similares